The Neural Spark: Dihexa and Cerebrolysin 🧠⚡
Dihexa and Cerebrolysin tell different stories about neural repair: a compromised preclinical foundation, a positive rehabilitation signal, and clinical evidence that resists a simple verdict.
🎧 Listen to this article:
🧠TWO NAMES, TWO DIFFERENT RESEARCH PROBLEMS
A convincing neural-repair story needs more than an interesting molecule. It needs experiments that can be trusted, outcomes that matter to patients, and a clear account of what happened when the original promise met a more demanding test. Dihexa and Cerebrolysin expose different weak points in that chain.
Dihexa's history includes a retracted paper on its proposed mechanism and separate mouse research reporting improved learning-test performance.[1][3] Cerebrolysin has reached randomized human trials, including a positive study of arm recovery after stroke, but the wider stroke literature raises difficult questions about consistency and serious adverse events.[4][5][6] These are not equivalent evidence problems. Nor do they turn the compounds into alternatives, complements, or a combination supported by research.
Cognitive Conductors examined the distance between a biological signal and a useful cognitive outcome. This article asks a different question: how should the promise of neural repair be judged when the research itself changes status, or when apparently conflicting clinical results measure different things?